Aziz Mottiwala Biography and Net Worth

Aziz has over 20 years of biopharmaceutical industry leadership experience in several therapeutic areas, including over 10 years in the eye care space. Prior to joining Tarsus, Aziz was Chief Commercial Officer at Opiant Pharmaceuticals, overseeing all aspects of commercial strategy for the company’s addiction medicine portfolio. Before that, he was Senior Vice President and Head of Commercial at Avanir Pharmaceuticals. He also spent over 10 years at Allergan (an AbbVie company), most recently as Vice President of Marketing for the company’s eye care franchise, where he helped grow the business to over $2 billion in revenue across a diverse portfolio including Restasis® and Lumigan®, as well as several other devices and OTC product lines.

Previously, Aziz held commercial leadership roles at Valeant, IMS Health (now IQVIA), and Aventis Pharmaceuticals (now Sanofi). He received a BS in biochemistry from the University of California San Diego and an MBA in marketing and finance from the Marshall School of Business at the University of Southern California. He is also heavily active in the community and serves on the boards of the Orange County nonprofit OneOC and Octane.

What is Aziz Mottiwala's net worth?: The estimated net worth of Aziz Mottiwala is at least $2.94 million as of March 18th, 2024. Mr. Mottiwala owns 54,075 shares of Tarsus Pharmaceuticals stock worth more than $2,942,221 as of December 24th. This net worth approximation does not reflect any other assets that Mr. Mottiwala may own. Learn More about Aziz Mottiwala's net worth.
How do I contact Aziz Mottiwala?: The corporate mailing address for Mr. Mottiwala and other Tarsus Pharmaceuticals executives is , , . Tarsus Pharmaceuticals can also be reached via phone at 949-409-9820 and via email at [email protected]. Learn More on Aziz Mottiwala's contact information.
Has Aziz Mottiwala been buying or selling shares of Tarsus Pharmaceuticals?: Aziz Mottiwala has not been actively trading shares of Tarsus Pharmaceuticals over the course of the past ninety days. Most recently, Aziz Mottiwala sold 4,766 shares of the business's stock in a transaction on Monday, March 18th. The shares were sold at an average price of $30.60, for a transaction totalling $145,839.60. Following the completion of the sale, the insider now directly owns 54,075 shares of the company's stock, valued at $1,654,695. Learn More on Aziz Mottiwala's trading history.
Who are Tarsus Pharmaceuticals' active insiders?: Tarsus Pharmaceuticals' insider roster includes D. Ackermann (Director), Bobak Azamian (CEO), and Aziz Mottiwala (Insider). Learn More on Tarsus Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Tarsus Pharmaceuticals?: During the last year, insiders at the sold shares 5 times. They sold a total of 32,496 shares worth more than $911,337.60. The most recent insider tranaction occured on March, 18th when insider Aziz Mottiwala sold 4,766 shares worth more than $145,839.60. Insiders at Tarsus Pharmaceuticals own 8.3% of the company. Learn More about insider trades at Tarsus Pharmaceuticals.
Information on this page was last updated on 3/18/2024.

Aziz Mottiwala Insider Trading History at Tarsus Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/18/2024	Sell	4,766	$30.60	$145,839.60	54,075
7/19/2023	Sell	2,400	$20.05	$48,120.00	45,806
6/8/2023	Sell	100	$20.00	$2,000.00	48,086
6/6/2023	Sell	2,143	$18.61	$39,881.23	50,686
11/15/2022	Sell	6,857	$17.72	$121,506.04	49,729
11/8/2021	Sell	1,889	$28.11	$53,099.79
11/4/2021	Sell	100	$28.03	$2,803.00
11/2/2021	Sell	6,000	$26.78	$160,680.00
9/10/2021	Sell	2,593	$22.15	$57,434.95	58,203

Aziz Mottiwala Buying and Selling Activity at Tarsus Pharmaceuticals

Tarsus Pharmaceuticals Company Overview

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Today's Range

Now: $54.12

$53.66

$54.88

50 Day Range

MA: $46.87

$36.45

$54.41

2 Week Range

Now: $54.12

$18.99

$56.77

Volume

51,358 shs

Average Volume

709,215 shs

Market Capitalization

$2.07 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.04

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong

From Brownstone Research | Ad

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.